{"filing":{"accession_number":"0001193125-26-314587","cik":"0001821825","ticker":"OGN","company_name":"Organon \u0026 Co.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"d128953d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821825/000119312526314587/d128953d8k.htm"},"events":[{"id":20192,"run_id":18177,"accession_number":"0001193125-26-314587","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This 8-K Item 5.07 discloses the results of a special stockholder meeting held on July 23, 2026, where shareholders voted on two proposals: (1) adoption of a Merger Agreement with Sun Pharmaceutical entities, which passed with 192.8 million votes for and 2.6 million against, and (2) advisory approval of merger-related executive compensation, which also passed. The disclosure includes voting tallies, quorum information, and record date details—all hallmarks of shareholder vote results. The merger itself is material, and the shareholder approval is a critical milestone in the transaction's completion.","company_name":"Organon \u0026 Co.","ticker":"OGN","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19492,"accession_number":"0001193125-26-314587","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This 8-K Item 5.07 discloses the results of a special stockholder meeting held on July 23, 2026, where shareholders voted on two proposals: (1) adoption of a Merger Agreement with Sun Pharmaceutical entities, which passed with 192.8 million votes for and 2.6 million against, and (2) advisory approval of merger-related executive compensation, which also passed. The disclosure includes voting tallies, quorum information, and record date details—all hallmarks of shareholder vote results. The merger itself is material, and the shareholder approval is a critical milestone in the transaction's completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T21:14:36.474028+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19492,"accession_number":"0001193125-26-314587","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This 8-K Item 5.07 discloses the results of a special stockholder meeting held on July 23, 2026, where shareholders voted on two proposals: (1) adoption of a Merger Agreement with Sun Pharmaceutical entities, which passed with 192.8 million votes for and 2.6 million against, and (2) advisory approval of merger-related executive compensation, which also passed. The disclosure includes voting tallies, quorum information, and record date details—all hallmarks of shareholder vote results. The merger itself is material, and the shareholder approval is a critical milestone in the transaction's completion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T21:14:36.474028+00:00","company_name":"Organon \u0026 Co.","ticker":"OGN","filing_date":"2026-07-23"}]}